Sort   by:  
 Page size 
TranscriptomicsPredominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma.
One third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within six months. Treatment options for these patients remain limited. Here we analyse twenty BRAFV600 mutant melanoma metastases derived from 10 patients treated with the combination of deb...
ORGANISM(S): Homo sapiens 
2014-12-03 | E-GEOD-61992 | biostudies-arrayexpress
TranscriptomicsSpectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma
Multiple BRAF inhibitor resistance mechanisms have been described, however their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. Excised progressing BRAFV600 mutant melanoma metastases (Prog) from patients treated...
ORGANISM(S): Homo sapiens 
2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress
TranscriptomicsBRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
Prediction of outcome for melanoma patients with surgically-resected macroscopic nodal metastases is very imprecise. We performed a comprehensive clinicopathologic assessment of fresh-frozen macroscopic nodal metastases and the preceding primary melanoma, somatic mutation profiling and gene expressi...
ORGANISM(S): Homo sapiens 
2013-12-10 | E-GEOD-53118 | biostudies-arrayexpress
Genomics20210708_EGA_Melanoma_mk2 - samples
Illumina platform whole genome sequencing data for matched tumour-normal DNA samples from 570 melanoma patients
EGAD00001008798 | EGA
Genomics20190219_EGA_MelanomaOnTreatment - samples
Illumina platform sequencing data for matched tumour-normal DNA samples from 77 melanoma patients participating in a study investigating response to immunotherapy. Selected cases also have RNA sequencing of the tumour.
EGAD00001004869 | EGA
Genomics20181113_EGA_MELA_Naevus - samples
Aligned, merged and deduplicated BAM files from HiSeq whole genome sequencing of 28 samples: matched tumour-normal pairs from 14 melanocytic nevi cases
EGAD00001004474 | EGA
Genomics20191008_EGA_MELA_Acral - samples
Illumina platform sequencing of whole genome libraries prepared from paired tumour/normal samples from 87 cases of melanoma Acral subtype. 63 cases also have RNASeq sequencing from the tumour sample.
EGAD00001005500 | EGA
Genomics20191008_EGA_MELA_Uveal - samples
Illumina platform sequencing of whole genome libraries prepared from paired tumour/normal samples from 103 cases of melanoma Uveal subtype
EGAD00001005454 | EGA
Genomics20191204_EGA_MELA_Rizos - samples
79 RNAseq samples from 56 patients with melanoma who have undergone immune checkpoint blockade immunotherapy.
EGAD00001005738 | EGA
GenomicsMELA-AU_WGS_20170516 - samples
Aligned, merged and deduplicated BAM files from HiSeq whole genome sequencing of 366 samples: matched tumour-normal pairs from 183 melanoma cases comprising 48 primary melanomas, 15 cell lines, and 120 metastases. Sequencing was performed on the Illumina HiSeq 2000 and Xten platforms at Australian a...
EGAD00001003388 | EGA
Sort   by:  
 Page size